Details of the Drug Combination

General Information of Drug Combination (ID: DCR127T)

Drug Combination Name
PF-4494700 PF-4494700
Indication
Disease Entry Status REF
Glioblastoma Phase 1 [1]
Component Drugs PF-4494700   DMJ7IKW PF-4494700   DMJ7IKW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of PF-4494700
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 3 [2]
Dementia 6D80-6D86 Phase 3 [3]
PF-4494700 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Advanced glycosylation end product receptor (AGER) TTMO9HF RAGE_HUMAN Antagonist [4]
------------------------------------------------------------------------------------
Indication(s) of PF-4494700
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 3 [2]
Dementia 6D80-6D86 Phase 3 [3]
PF-4494700 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Advanced glycosylation end product receptor (AGER) TTMO9HF RAGE_HUMAN Antagonist [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05635734) Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8317).
4 Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9.